par Liefferinckx, Claire ;Verstockt, Bram;Gils, Ann;Noman, Maja;Van Kemseke, Catherine;Macken, Elisabeth;De Vos, Martine;Van Moerkercke, W.;Rahier, Jean François;Bossuyt, Peter;Dutré, Joris;Humblet, Evelien;Staessen, Dirk A J D.;Peeters, Harald;Van Hootegem, Ph;Louis, Edouard;Franchimont, Denis ;Baert, Filip;Vermeire, Séverine
Référence Journal of Crohn's and Colitis, 13, 11, page (1401-1409)
Publication Publié, 2019-10-01
Référence Journal of Crohn's and Colitis, 13, 11, page (1401-1409)
Publication Publié, 2019-10-01
Article révisé par les pairs
Résumé : | Background: Ustekinumab [UST] was recently approved in Europe for the treatment of moderate to severe Crohn's disease [CD]. Long-term real-world data are currently scarce for CD patients previously exposed to several biologics. Methods: This is an observational, national, retrospective multicentre study. Patients received intravenous UST ~6 mg/kg at baseline, with 90 mg subcutaneously thereafter every 8 weeks. Response and remission rates were assessed at Weeks 8, 16, and 52. Results: Data from 152 patients were analysed. All patients were exposed to at least one anti-TNFα agent, with 69.7% were exposed to even two anti-TNFα and vedolizumab. After 1 year, 42.1% and 25.7% of patients had experienced clinical response and clinical remission, respectively, and 38.8% and 24.3% had achieved steroid-free clinical response and remission, respectively; 38.8% of patients discontinued therapy during the 12 months of follow-up. Colonic location was predictive of clinical response at 1 year, and low body mass index [BMI] at baseline was a negative predictor of clinical remission. Resolution of arthralgia was associated with clinical response over time. De novo arthralgia was reported by 17.9% of patients at Week 8 and 13.5% of patients at Week 52. No impact of UST on arthralgia was observed in patients with concomitant ankylosing spondylitis [n = 17]. Others adverse events were reported in 7.2% of patients. Conclusions: This real-world cohort study confirms the effectiveness of UST in CD patients previously exposed to several biologics. Ustekinumab was well tolerated with respect to adverse events. Podcast: This article has an associated podcast which can be accessed at https://academic.oup.com/ecco-jcc/pages/podcast. |